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Abstract
Background: There is a growing understanding that depression is associated with systemic inflammation. Statins and 
aspirin have anti-inflammatory properties. Given these agents have been shown to reduce the risk of a number of diseases 
characterized by inflammation, we aimed to determine whether a similar relationship exists for mood disorders (MD). 
Methods: This study examined data collected from 961 men (24–98 years) participating in the Geelong Osteoporosis Study. 
MD were identified using a semistructured clinical interview (SCID-I/NP). Anthropometry was measured and information on 
medication use and lifestyle factors was obtained via questionnaire. Two study designs were utilized: a nested case-control 
and a retrospective cohort study.
Results: In the nested case-control study, exposure to statin and aspirin was documented for 9 of 142 (6.3%) cases and 234 
of 795 (29.4%) controls (P < .001); after adjustment for age, exposure to these anti-inflammatory agents was associated with 
reduced likelihood of MD (OR 0.2, 95%CI 0.1–0.5). No effect modifiers or other confounders were identified. In the retrospective 
cohort study of 836 men, among the 210 exposed to statins or aspirin, 6 (2.9%) developed de novo MD during 1000 person-years 
of observation, whereas among 626 nonexposed, 34 (5.4%) developed de novo MD during 3071 person-years of observation. The 
hazard ratio for de novo MD associated with exposure to anti-inflammatory agents was 0.55 (95%CI 0.23–1.32). 
Conclusions: This study provides both cross-sectional and longitudinal evidence consistent with the hypothesis that statin 
and aspirin use is associated with a reduced risk of MD.
Keywords: Statins, aspirin, mood disorder, depression, cytokines, epidemiology, immune system, inflammation, prevention
 by guest on N
ovem
ber 14, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
2 | International Journal of Neuropsychopharmacology, 2016
While the underlying pathophysiology of mood disorders (MD) 
is not fully understood, there is now an extensive body of data 
showing they are associated with a chronic, low-grade inflam-
matory response (Berk et al., 2013a). Further support has come 
from studies of patient groups with immune-related diseases, 
with which depression is highly comorbid (Dantzer et al., 2008) 
and studies where infusion of cytokines robustly induces symp-
toms of depression (DellaGioia and Hannestad, 2010). Statins 
(3-hydroxy-3-methylglutaryl coenzyme A  reductase inhibitors) 
primarily used in the treatment of hypercholesterolemia and 
prevention of cardiovascular disease, and aspirin (acetylsalicylic 
acid), primarily used as an analgesic and/or antiplatelet agent, 
both have antiinflammatory properties (Dinarello, 2010). Given 
these agents are now known to reduce the risk of a number of 
diseases characterized by inflammation and our previous find-
ing of an inverse association with depression in women (Pasco 
et al., 2010), we aimed to determine whether a similar relation-
ship exists for men.
Data were derived from an age-stratified, random popula-
tion-based sample of men enrolled in the Geelong Osteoporosis 
Study, a large, ongoing study located in southeastern Australia 
(Pasco et  al., 2012). Further details of the study have been 
published elsewhere (Pasco et  al., 2012). Briefly, between 2001 
and 2006, 1540 men (response 67.0%) were recruited from 
the Australian Commonwealth electoral rolls for the Barwon 
Statistical Division. Of the 1540 participants, 978 returned for 
5-year follow-up assessment between 2006 and 2011 (81.0% 
response for those alive and contactable). For the current analy-
ses, participants for whom psychiatric data were not available 
(n = 17) were excluded, resulting in a sample of 961 men aged 
24 to 98 years. The study was approved by the Barwon Health 
Human Research Ethics Committee, and written informed con-
sent was obtained from all participants.
The Structured Clinical Interview for Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Non-
patient edition was conducted at the Geelong Osteoporosis 
Study 5-year follow-up and used to assess lifetime history of 
MD. Self-reported medication use was documented by ques-
tionnaires administered at each visit. Participants were asked 
to bring a list of medications or containers to assist with accu-
rate recording of details. Anthropometry was measured and 
information on lifestyle factors was obtained via written ques-
tionnaire. Socio-economic status was ascertained using Socio-
Economic Index For Areas index scores.
Two study designs were utilized: a nested case-control and a 
retrospective cohort study. The former identified ‘cases’ as sub-
jects diagnosed with a MD and ‘controls’ were MD-free (ever). 
Exposure to statins and/or aspirin was recognized if exposure 
preceded the first-onset MD episode for cases and the 5-year 
assessment for controls. Multivariable logistic regression was 
used to calculate odds ratios (ORs) with 95% CI for de novo MD 
for those exposed to antiinflammatory agents in comparison 
with those not exposed. The latter design comprised partici-
pants without a history of MD at baseline who were followed 
from baseline until a first episode of MD or until the end of the 
5-year follow-up period. The risk for de novo MD associated 
with exposure to antiinflammatory agents was examined using 
multivariable Cox proportional hazards regression models. 
Covariates including age, weight, height, alcohol, smoking, phys-
ical activity, socio-economic status, and use of antidepressants, 
sex hormones, nonsteroidal antiinflammatory drugs, other 
hyperlipidaemia agents, and other anticoagulants were tested 
as confounders or effect modifiers in each multivariable model.
Among 961 men, 165 were diagnosed with a MD (cases) and 
796 had no history of MD (controls). Twenty-three cases were 
excluded due to participants having an episode of MD prior 
Table 1. Characteristics of MD Cases and Controls Included in the Nested Case-Control Study and Baseline Characteristics for Subjects in the 
Retrospective Cohort Study According to Exposure to the Antiinflammatory Agents Statins and Aspirin
Case Control Study Retrospective Cohort Study
Cases Controls
P-value
Exposed Not exposed
P-valuen = 142 n = 795 n = 210 n = 626
Age, y 50.4 (41.5–59.9) 61.3 (47.0–75.9) <.001 71.8 (62.7–77.5) 49.5 (37.5–62.6) <.001
Height, cm 176.9 ± 6.7 174.6 ± 7.3 .001 172.1 ± 6.9 175.9 ± 6.9 <.001
Weight, kg 83.7 (75.8–94.0) 82.3 (74.0–92.4) .216 81.7 (73.2–90.7) 81.7 (73.9–91.3) .854
Alcohol, g/d 17.8 (2.7–35.6) 11.9 (2.2–28.3) .047 12.1 (1.3–30.0) 15.3 (3.0–29.8) .064
Smoking (current) 22 (15.5%) 88 (11.1%) .131 7 (3.3%) 92 (14.7%) <.001
Physical activity (active) 103 (72.5%) 570 (72.2%) .925 164 (78.1%) 512 (81.8%) .239
 Socio-economic status .864 .008
 Quintile 1 (most disadvantaged) 22 (15.5%) 130 (16.4%) 42 (20.0%) 96 (15.3%)
 Quintile 2 25 (17.6%) 167 (21.0%) 58 (27.6%) 115 (18.4%)
 Quintile 3 28 (19.7%) 153 (19.3%) 36 (17.1%) 125 (20.0%)
 Quintile 4 31 (21.8%) 168 (21.1%) 34 (16.21%) 141 (22.5%)
 Quintile 5 36 (25.4%) 177 (22.3%) 40 (19.1%) 149 (23.8%)
Medication use (current)
 Antidepressants 27 (19.0%) 32 (4.0%) <.001 12 (5.7%) 13 (2.1%) .007
 Hormone therapy 1 (0.7%) 5 (0.6%) 1.000 7 (3.3%) 7 (1.1%) .030
 Nonsteroidal antiinflammatory drugs 10 (7.0%) 57 (7.2%) .957 29 (13.8%) 50 (8.0%) .013
 Statins 4 (2.8%) 178 (22.4%) <.001 – –
 Aspirin 8 (5.6%) 140 (17.6%) <.001 – –
 Aspirin/statins (pooled) 9 (6.3%) 234 (29.4%) <.001 – –
MD (de novo) – – 6 (2.9%) 34 (5.4%) .130
Abbreviation: MD, mood disorder.
Values are given as mean (± SD), median (IQR), or n (%).
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to exposure to either statins or aspirin, and one control was 
excluded because of an unknown medication status. Thus, 142 
cases and 795 controls were considered. Participant characteris-
tics are shown in Table 1. At the time of interview, 182 men (19.4%) 
were exposed to statins; 50 (27.5%) used Simvastatin, 87 (47.8%) 
used Atorvastatin, 28 (15.4%) used Pravastatin, and 17 (9.3%) used 
Rosuvastatin. Median duration of use was 6.3 (IQR 2.4–10.2) years. 
Exposure to statins was documented for 4 of 142 (2.8%) cases and 
178 of 795 (22.4%) controls (P < .001); after adjustment for age, the 
OR for de novo MD was 0.1 (95%CI 0.1–0.4, P ≤ .001).
One hundred and forty-eight (15.8%) men had been exposed to 
aspirin. Median duration of use was 8.4 (3.9–13.0) years. Exposure 
to aspirin was documented for 8 of 142 (5.6%) cases and 140 of 795 
(17.6%) controls (P ≤ .001); after adjustment for age and antidepres-
sant use, the OR for de novo MD was 0.4 (95%CI 0.2–0.9, P = 0.03). 
When statin and aspirin users were pooled (n = 243, 25.9%), expo-
sure was documented for 9 of 142 (6.3%) cases and 234 of 795 
(29.4%) controls (P < .001). Following adjustment for age, exposure 
to these antiinflammatory agents was associated with reduced 
risk of de novo MD (OR = 0.2, 95%CI 0.1–0.5, P < .001). For all models, 
no effect modifiers or other confounders were identified.
In the retrospective cohort study of 836 men, 210 had been 
exposed to statins (n=141; 39 [27.7%] used Simvastatin, 60 
[42.6%] used Atorvastatin, 37 [26.2%] used Pravastatin, 2 [1.4%] 
used Rosuvastatin, 2 [14%] used Fluvastain, and 1 [0.7%] was 
unknown) or aspirin (n = 137). Participant characteristics are 
shown in Table 1. Among the 210 exposed men, 6 (2.9%) devel-
oped de novo MD during 1000 person-years of observation, 
whereas among 626 nonexposed, 34 (5.4%) developed de novo 
MD during 3071 person-years of observation. The hazard ratio 
for de novo MD associated with exposure to antiinflammatory 
agents was 0.55 (95%CI 0.23–1.32, P = .18). A Kaplan-Meier sur-
vival plot (Figure 1) shows the probability of remaining free of de 
novo MD for men exposed and not exposed to the antiinflam-
matory agents statins and aspirin.
This study thus provides both cross-sectional and longitu-
dinal evidence consistent with the hypothesis that statin and 
aspirin use is associated with a reduced risk of MD. Our find-
ings are consistent with both observational and clinical trials 
of healthy and cardiac populations in suggesting mood-related 
benefits are associated with statin and aspirin treatment 
(O’Neil et al., 2012; Berk et al., 2013b). Conversely, others have 
reported negative or no association (Hyyppa et al., 2003). Given 
the known antiinflammatory properties of statins and aspirin 
and the extensive body of evidence to suggest that depression 
is associated with a chronic, low-grade inflammatory response 
(Berk et al., 2013a) and oxidative and nitrosative stress (Moylan 
et al., 2014), a reduction in inflammation is a likely underlying 
explanatory mechanism.
There are several strengths and weaknesses that need to be 
taken into consideration. Our ability to incorporate both cross-
sectional and longitudinal study designs and identify depres-
sion by gold-standard clinical assessment are key strengths, as 
is our ability to test several potential confounding factors. In 
regards to limitations, recall bias is possible, as is residual or 
unrecognized confounding. Furthermore, power limitations pre-
vented subgroup analyses investigating severity and duration of 
MD, dose, duration, or individual agent effects and are likely to 
have limited our ability to detect significant differences in the 
retrospective cohort study given the large effect size.
In conclusion, these data augment the emerging evidence-
base suggesting that statins and/or aspirin may play a protec-
tive role in the development of depression. Well-conducted, 
randomized controlled trials investigating the potential of these 
agents in the treatment and prevention of MDs are now needed.
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